Article
Respiratory System
Rudolf M. Huber, Diego Kauffmann-Guerrero, Hans Hoffmann, Michael Flentje
Summary: Recent developments in the treatment of locally advanced nonsmall cell lung cancer have focused on integrating immunotherapy with radiotherapy, chemotherapy, and adjuvant targeted therapy. The importance of consolidation therapy, pathological evaluation, and investigation of immunological features and driver mutations in improving management and prognosis has been emphasized.
EUROPEAN RESPIRATORY REVIEW
(2021)
Article
Cardiac & Cardiovascular Systems
Junichi Soh, Seiichiro Sugimoto, Kei Namba, Akihiro Miura, Toshio Shiotani, Haruchika Yamamoto, Ken Suzawa, Kazuhiko Shien, Hiromasa Yamamoto, Mikio Okazaki, Kuniaki Katsui, Masaomi Yamane, Katsuyuki Kiura, Susumu Kanazawa, Shinichi Toyooka
Summary: Trimodality therapy is a common treatment option for locally advanced non-small cell lung cancer (LA-NSCLC) patients. Chronic lung injury (CLI) is a frequent complication after such treatment, often leading to cavity formation and chronic infections requiring surgical intervention. Further research on appropriate management for CLI post-trimodality therapy is needed.
ANNALS OF THORACIC SURGERY
(2021)
Article
Oncology
Shimpei Tsudaka, Hiromasa Yamamoto, Hiroki Sato, Kuniaki Katsui, Ken Suzawa, Kazuhiko Shien, Kentaroh Miyoshi, Shinji Otani, Mikio Okazaki, Seiichiro Sugimoto, Masaomi Yamane, Katsuyuki Kiura, Susumu Kanazawa, Shinichi Toyooka
Summary: The study aimed to evaluate the prognostic impact of postoperative NLR in LA-NSCLC patients. Results indicated that high postoperative NLR was an unfavorable prognostic factor and a promising indicator for postoperative treatment in this population.
ANNALS OF SURGICAL ONCOLOGY
(2021)
Review
Oncology
Kristin A. Higgins, Sonam Puri, Jhanelle E. Gray
Summary: The treatment of locally advanced non-small-cell lung cancer has undergone significant changes, with consolidative immunotherapy becoming the new standard of care. Despite improvements, further developments are needed for patients who experience disease progression after concurrent chemoradiation and immunotherapy, as well as those with driver mutations.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
Magdalena Zaborowska-Szmit, Marta Olszyna-Serementa, Dariusz M. Kowalski, Sebastian Szmit, Maciej Krzakowski
Summary: The combination of chemotherapy and radiotherapy is more beneficial in elderly patients with locally advanced unresectable non-small-cell lung cancer compared to radiotherapy alone. Sequential chemoradiotherapy may result in more complete response and less distant metastases in older patients, leading to significantly longer survival.
Article
Oncology
Tae Hoon Lee, Byung-Hee Kang, Hak Jae Kim, Hong-Gyun Wu, Joo Ho Lee
Summary: This study aimed to investigate the clinical effects and predictive factors of severe post-chemoradiotherapy pulmonary complications (PCPC) in locally advanced non-small cell lung cancer (LA-NSCLC). The results showed that PCPC was associated with lower overall survival but not disease progression rate. Hypoalbuminemia, DLCO, and lung V5 were identified as predictive factors for PCPC in LA-NSCLC patients.
CANCER RESEARCH AND TREATMENT
(2023)
Review
Oncology
Toon Allaeys, Lawek Berzenji, Patrick Lauwers, Suresh Krishan Yogeswaran, Jeroen M. H. Hendriks, Charlotte Billiet, Charlotte De Bondt, Paul E. Van Schil
Summary: This review summarizes the latest data on multimodality treatment options for stage IIIA-N2 locally advanced non-small cell lung cancer (NSCLC), including chemotherapy, radiation therapy, surgery, immunotherapy, and targeted therapy. The role of surgery is being redefined, and surgical resection after induction immunotherapy or targeted therapy has shown promising short-term results.
Review
Medical Laboratory Technology
Lea Sinoquet, William Jacot, Xavier Quantin, Catherine Alix-Panabieres
Summary: This study discusses the application of immune checkpoint inhibitors in the treatment of metastatic nonsmall cell lung cancer and focuses on the evaluation of blood biomarkers such as circulating cell-free DNA, circulating tumor DNA, blood tumor mutational burden, and circulating tumor cells. Monitoring these biomarkers during immunotherapy may assist clinicians in making therapeutic decisions.
CLINICAL CHEMISTRY
(2023)
Article
Oncology
Motoko Tachihara, Kayoko Tsujino, Takeaki Ishihara, Hidetoshi Hayashi, Yuki Sato, Takayasu Kurata, Shunichi Sugawara, Yoshimasa Shiraishi, Shunsuke Teraoka, Koichi Azuma, Haruko Daga, Masafumi Yamaguchi, Takeshi Kodaira, Miyako Satouchi, Mototsugu Shimokawa, Nobuyuki Yamamoto, Kazuhiko Nakagawa
Summary: This study investigated the efficacy and safety of durvalumab immunotherapy combined with concurrent radiotherapy for patients with locally advanced NSCLC. The results showed that this treatment approach achieved a high rate of 12-month progression-free survival and had tolerable adverse events. These findings suggest that durvalumab immunotherapy combined with curative radiotherapy may be a promising treatment option.
Article
Oncology
Xin Wang, Dong-Bing Zhao, Lin Yang, Yihebali Chi, Hong Zhao, Li-Ming Jiang, Jun Jiang, Yuan Tang, Ning Li, Wen-Yang Liu, Li-Zhou Dou, Shuang-Mei Zou, Li-Yan Xue, Jian-Song Ren, Yan-Tao Tian, Xu Che, Chun-Guang Guo, Xiao-Feng Bai, Yue-Min Sun, Shu-Lian Wang, Yong-Wen Song, Yue-Ping Liu, Hui Fang, Ye-Xiong Li, Jing Jin
Summary: This study compared the efficacy and safety of neoadjuvant chemotherapy and neoadjuvant chemoradiotherapy for locally advanced gastric cancer. The results showed that neoadjuvant chemoradiotherapy resulted in better tumor regression but did not improve the R0 resection rate. There was no significant difference in postoperative complications between the two groups.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Nicolas Girard, Maurice Perol, Gaetane Simon, Clarisse Audigier Valette, Radj Gervais, Didier Debieuvre, Roland Schott, Xavier Quantin, Bruno Coudert, Herve Lena, Matthieu Carton, Mathieu Robain, Thomas Filleron, Christos Chouaid
Summary: This study examined the patient profiles and clinical outcomes for different treatment strategies in a real-world setting for unresectable locally advanced NSCLC. The findings indicated that concurrent chemoradiotherapy is administered to the most fit patients, resulting in higher survival rates than those reported in landmark clinical trials. Long-term outcomes are similar after sequential or concurrent chemoradiotherapy.
Article
Oncology
Byung-Hee Kang, Xue Li, Jaeman Son, Changhoon Song, Hyun-Cheol Kang, Hak Jae Kim, Hong-Gyun Wu, Joo Ho Lee
Summary: In this study, we evaluated the clinical and dose-volumetric predictors of delayed lymphopenia in patients with locally advanced NSCLC after chemoradiotherapy. We found that delayed lymphopenia was associated with inferior overall survival and progression-free survival, and identified lung V5, baseline ALC, during-CRT ALC, and albumin nadir as significant predictors for delayed lymphopenia.
FRONTIERS IN ONCOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Alina Frey, Daniel Martin, Louisa D'Cruz, Emmanouil Fokas, Claus Rodel, Maximilian Fleischmann
Summary: The study assessed the C-reactive protein (CRP) to albumin ratio (CAR) as a prognostic score in locally advanced non-small-cell lung cancer (NSCLC) patients treated with CRT. The findings showed that elevated CAR was associated with worse outcomes, including poorer local control and shorter survival.
Article
Medicine, General & Internal
Deborah Schrag, Qian Shi, Martin R. Weiser, Marc J. Gollub, Leonard B. Saltz, Benjamin L. Musher, Joel Goldberg, Tareq Al Baghdadi, Karyn A. Goodman, Robert R. McWilliams, Jeffrey M. Farma, Thomas J. George, Hagen F. Kennecke, Ardaman Shergill, Michael Montemurro, Garth D. Nelson, Brian Colgrove, Vallerie Gordon, Alan P. Venook, Eileen M. O'Reilly, Jeffrey A. Meyerhardt, Amylou C. Dueck, Ethan Basch, George J. Chang, Harvey J. Mamon
Summary: Preoperative FOLFOX chemotherapy is as effective as preoperative chemoradiotherapy for locally advanced rectal cancer eligible for sphincter-sparing surgery.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Oncology
Wakako Daido, Takeshi Masuda, Nobuki Imano, Naoko Matsumoto, Kosuke Hamai, Yasuo Iwamoto, Yusuke Takayama, Sayaka Ueno, Masahiko Sumii, Hiroyasu Shoda, Nobuhisa Ishikawa, Masahiro Yamasaki, Yoshifumi Nishimura, Shigeo Kawase, Naoki Shiota, Yoshikazu Awaya, Tomoko Suzuki, Soichi Kitaguchi, Kazunori Fujitaka, Yasushi Nagata, Noboru Hattori
Summary: Interstitial lung disease (ILD) is a life-threatening toxicity caused by chemoradiotherapy and durvalumab. In non-small-cell lung cancer patients, pre-existing interstitial lung abnormalities (ILAs) may be independent risk factors for ILD during treatment with durvalumab. Patients with ILAs should be monitored closely for the development of severe ILD during durvalumab therapy.
